Kazia Therapeutics Limited filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission on November 17, 2026, covering the fiscal year ended June 30, 2026.

Key Highlights

  • Outstanding shares: The company reported 6,346,508,234 ordinary shares outstanding as at June 30, 2026.
  • Listed securities: American Depositary Shares, each representing five-hundred ordinary shares, are listed on the Nasdaq Capital Market under the symbol KZIA.
  • Accounting standards: Financial statements were prepared using International Financial Reporting Standards as issued by the International Accounting Standards Board.
  • Filer status: The registrant is classified as an accelerated filer and is not an emerging growth company.
  • SOX 404(b) attestation: The registrant indicated that the registered public accounting firm that prepared or issued its audit report filed a report on and attestation to management's assessment of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
  • Clinical programs: The filing references ongoing and planned studies in indications including advanced triple-negative breast cancer, HR+/HER2- breast cancer, pMMR colorectal cancer, brain metastases, glioma, and primary central nervous system lymphoma, among others.

Kazia Therapeutics 20-F: Fiscal Year 2026 Annual Disclosure Details

Kazia Therapeutics Limited, an Australian biopharmaceutical company incorporated in New South Wales and headquartered at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney, filed its annual report on Form 20-F with the SEC on November 17, 2026. The filing covers the fiscal year ended June 30, 2026, and was submitted under the annual report provision of Section 13 or 15(d) of the Securities Exchange Act of 1934. The company's commission file number is 0-29962, according to the filing.

According to the filing, Kazia's American Depositary Shares trade on NASDAQ:KZIA, with each ADS representing five-hundred ordinary shares. The total number of ordinary shares outstanding at the close of the fiscal year was 6,346,508,234. The registrant confirmed it had filed all required reports during the preceding 12 months and had submitted all required Interactive Data Files electronically as required by Rule 405 of Regulation S-T.

The filing states that the company is not a well-known seasoned issuer and is not a shell company. Kazia reported that it is not required to use the extended transition period for new accounting standards, as it is not an emerging growth company. The annual report includes disclosures spanning clinical development activities, operating and financial review, corporate governance, controls and procedures, and cybersecurity. The filing also contains forward-looking statements, which the company identifies as subject to risks and uncertainties, and which it cautions may differ materially from actual outcomes. John Friend, M.D., is identified as the company contact person.

What Was Disclosed

Kazia Therapeutics Limited submitted its fiscal year 2026 annual report on Form 20-F, disclosing 6,346,508,234 ordinary shares outstanding, its accelerated filer status, IFRS-based financial statements, and ongoing clinical development activity across multiple oncology indications.